Loading....
The RPGRIP1 Project
to prevent vision loss
Odylia is excited to announce the End of Year Campaign to Prevent Vision Loss. Our goal is to raise $95,000 by December 31st. Funds will be used to initiate the manufacturing process for the RPGRIP1 gene therapy. This amount represents 10% of the goal for the first phase of the program and is a critical point for jumpstarting drug development activities.
An anonymous donor is helping us with a matching gift challenge. Every gift made before December 31 will be matched dollar-for-dollar (up to $25,000). Your gift will be doubled!
The Path Forward
Odylia Therapeutics is a nonprofit (501c3) biotech focused on accelerating the development of treatments for people with rare diseases. Odylia is developing a gene therapy to treat vision loss caused by RPGRIP1 mutations. Currently, Odylia is conducting late-stage preclinical experiments and preparing for clinical trials.
How Can YOU Help?
Consider donating to the RPGRIP1 Project. Funds will be used to manufacture the gene therapy and to conduct critical toxicology studies. Without philanthropic support, this promising treatment may stall. Your donation will help ensure that it has the opportunity to reach patients and preserve their vision. Together, we can make this happen. You can support Odylia and our other projects by following this link.
Thank You!
Working together, we can develop treatments to prevent vision loss. We are so grateful for your support and look forward to sharing our success story!
We would LOVE it if you could let your friends and loved ones know about
your support of our work by sharing this via social media using the links below!